



# MEDI-CAL UPDATE

EDS • PO Box 13029 • Sacramento, CA • 95813-4029

www.medi-cal.ca.gov

Pharmacy Bulletin 662

August 2007

## Contents

Medi-Cal List of Contract Drugs .....	1
Diabetic Testing Product Additions .....	4
Authorized Drug Manufacturer Labeler Codes Update .....	4
Nicoderm CQ Billing Update .....	5
Persistence of Beta-Blocker Treatment After Myocardial Infarction .....	6

## Medi-Cal List of Contract Drugs

The following provider manual sections have been updated: *Drugs: Contract Drugs List Part 1 – Prescription Drugs* and *Drugs: Contract Drugs List Part 2 – Over-the-Counter Drugs*.

### Changes, effective August 14, 2007

<u>Drug</u>	<u>Strength and/or Size</u>	<u>Billing Unit</u>
* ESCITALOPRAM OXALATE		
* <b>Restricted to NDC labeler code 00456 (Forest Pharmaceuticals, Inc.) only.</b>		
Solution, oral	5 mg/5 cc	cc
Tablets	5 mg	ea
	10 mg	ea
	20 mg	ea
* NIACIN		
* Restricted to NDC labeler codes <b>00074 (Abbot Laboratories) and</b> 60598 (KOS Pharmaceuticals, Inc.) only.		
Tablets, extended release	500 mg	ea
( <u>includes</u> film coated tablets)	750 mg	ea
	1000 mg	ea

### Changes, effective September 1, 2007

<u>Drug</u>	<u>Strength and/or Size</u>	<u>Billing Unit</u>
BUDESONIDE		
Oral powder for inhalation	* <b>90 mcg/inhalation</b>	<b>60 inhalations/container</b>
	<b>180 mcg/inhalation</b>	<b>120 inhalations/container</b>
	200 mcg/inhalation	200 inhalations/container
* <b>Restricted to a maximum quantity per dispensing of one container in any 30-day period for the 90 mcg/inhalation strength only.</b>		
<b>Note:</b> The billing unit for this product is each container.		
* Suspension for inhalation	0.25 mg/2 cc ampule	cc
	0.5 mg/2 cc ampule	cc
* Restricted to use <b>by</b> individuals less than <b>4</b> years <b>of age</b> .		

Please see **Contract Drugs**, page 3

**EDS/MEDI-CAL HOTLINES**

Border Providers .....(916) 636-1200  
CDHS Medi-Cal Fraud Hotline ..... 1-800-822-6222  
Telephone Service Center (TSC) ..... 1-800-541-5555  
Provider Telecommunications Network (PTN)..... 1-800-786-4346

**EDS • PO Box 13029 • Sacramento, CA • 95813-4029**

*For a complete listing of specialty programs and hours of operation, please refer to the Medi-Cal Directory in the provider manual.*



***OPT OUT** is a service designed to save time and increase Medi-Cal accessibility. A monthly e-mail containing direct Web links to current bulletins, manual page updates, training information, and more is now available. Simply “opt-out” of receiving this same information on paper, through standard mail. To download the OPT-OUT enrollment form or for more information, go to the Medi-Cal Web site at [www.medi-cal.ca.gov](http://www.medi-cal.ca.gov), and click the “Learn how...” OPT OUT link on the right side of the home page.*

**Stop Illegal Tobacco Sales**

The simplest way to stop illegal tobacco sales to minors is for merchants to check ID and verify the age of the tobacco purchasers. Report illegal tobacco sales to 1-800-5-ASK-4-ID.

For more information, see the California Department of Health Services Web site at <http://www.dhs.ca.gov>.

**MEDI-CAL FRAUD**

**IS AGAINST THE**

**LAW**

**MEDI-CAL FRAUD COSTS TAXPAYERS MILLIONS  
EACH YEAR AND CAN ENDANGER  
THE HEALTH OF CALIFORNIANS.**

**HELP PROTECT MEDI-CAL AND YOURSELF  
BY REPORTING YOUR OBSERVATIONS TODAY.**

**CDHS MEDI-CAL FRAUD HOTLINE  
1-800-822-6222**

**THE CALL IS FREE AND YOU CAN REMAIN ANONYMOUS.**

Knowingly participating in fraudulent activities can result in prosecution and jail time. Help prevent Medi-Cal fraud.

Contract Drugs (continued)

Changes, effective September 1, 2007 (continued)

<u>Drug</u>	<u>Strength and/or Size</u>	<u>Billing Unit</u>
NIACIN AND LOVASTATIN		
Tablets (containing extended release niacin)	500 mg/20 mg	ea
	750 mg/20 mg	ea
	1000 mg/20 mg	ea
	<b><u>1000 mg/40 mg</u></b>	<b><u>ea</u></b>
* VENLAFAXINE HCL		
<b>* <u>Restricted to NDC labeler code 00008 (Wyeth Pharmaceuticals, Inc.) only.</u></b>		
Capsules, extended release	37.5 mg	ea
	75 mg	ea
	150 mg	ea
* NICOTINE		
Transdermal system	7 mg/24 hr	ea
	14 mg/24 hr	ea
	21 mg/24 hr	ea
<b>(NDC labeler codes 00766 and 00135 [GlaxoSmithKline] only.)</b>		
* Pharmacy must obtain a letter or certificate of enrollment for the patient from a behavioral modification smoking cessation program. Also restricted to (1) a quantity of 14 patches per dispensing; (2) five dispensings in a 70-day period; (3) therapy lasting up to ten weeks from the dispensing date of the first prescription; <b><u>and (4) NDC labeler code 00135 (GlaxoSmithKline) only.</u></b>		

Change, effective November 1, 2007

<u>Drug</u>	<u>Strength and/or Size</u>	<u>Billing Unit</u>
FLUOXETINE HCL		
Capsules	10 mg	ea
	20 mg	ea
	<del>40 mg</del>	<del>ea</del>
* Capsules, delayed release enteric-coated pellets	90 mg	ea
<b>* <u>Restricted to claims with dates of service on or before October 31, 2007. Continuing care with a date of service on or after November 1, 2007 is available when all of the following conditions are met: 1) The beneficiary has a Medi-Cal fee-for-service paid claim for this drug on or before October 31, 2007; 2) A claim has been submitted and paid at least every 100 days; and 3) The claim being submitted is within 100 days of the date of service of the last paid claim submitted.</u></b>		
Tablets	10 mg	ea
Solution	20 mg/5 cc	cc

These updates are reflected on manual replacement pages [drugs cdl p1a 18](#) (Part 2), [drugs cdl p1b 5 and 14](#) (Part 2), [drugs cdl p1c 3](#) (Part 2), [drugs cdl p1d 21](#) (Part 2) and [drugs cdl p2 9](#) (Part 2).

### Diabetic Testing Product Additions

Effective October 1, 2007, the Department of Health Care Services (DHCS) added products to the list of contracted diabetic supplies for Abbott Diabetes Care. These items must be billed by Pharmacy providers using an 11-digit Universal Product Number (UPN) to establish rebates and other cost-saving mechanisms.

Items not included in the list of contracted diabetic supplies are not Medi-Cal benefits, and therefore will not be granted prior authorization or a *Treatment Authorization Request* (TAR). California Children’s Services/Genetically Handicapped Persons Program (CCS/GHPP) authorization must match the exact UPN granted under authorization for payment.

#### Additions to Medical Supplies List

The following products have been added to the *Medical Supplies List* section:

<u>Description</u>	<u>Billing Code</u>	Bill Quantity In Total <u>Number of</u>
FreeStyle Lite Test Strips (50)	99073070822	Strip
FreeStyle Lite Test Strips (100)	99073070827	Strip

This information is reflected on manual replacement page mc sup lst1 13 (Part 2).

### Authorized Drug Manufacturer Labeler Codes Update

The *Drugs: Contract Drugs List Part 5 – Authorized Drug Manufacturer Labeler Codes* section has been updated as follows.

#### Reinstatement, effective July 1, 2004

<u>NDC Labeler Code</u>	<u>Contracting Company’s Name</u>
60242	NEIL LABORATORIES, INC.

#### Additions, effective October 1, 2004

<u>NDC Labeler Code</u>	<u>Contracting Company’s Name</u>
66378	PRESUTTI LABORATORIES, INC.
68188	ALLIANT PHARMACEUTICALS
68712	JSJ PHARMACEUTICALS
68782	EYETECH PHARMACEUTICALS, INC.

#### Terminations, effective October 1, 2004

<u>NDC Labeler Code</u>	<u>Contracting Company’s Name</u>
08290	BD BECTON DICKINSON
63807	EXCELSIOR MEDICAL CORP.
65759	D & K HEALTHCARE RESOURCES, INC.

These updates are reflected on manual replacement pages drugs cdl p5 5 and 11 thru 15 (Part 2).

## Nicoderm CQ Billing Update

The Department of Health Care Services (DHCS) is removing National Drug Code (NDC) labeler code 00766 as a valid labeler code for Nicotine transdermal patches in the *Drugs: Contract Drugs List Part 2 – Over-the-Counter Drugs* section of the Part 2 manual.

### Background

GlaxoSmithKline (GSK) advised DHCS that it would be transitioning the NDC numbers for its Nicoderm CQ products from labeler code 00766 to labeler code 00135. Therefore, Nicotine transdermal patches are currently restricted to NDC labeler codes 00766 and 00135 in the *Drugs: Contract Drugs List Part 2 – Over-the-Counter Drugs* section of the Part 2 manual.

Effective July 1, 2007, GSK terminated its federal rebate contract for labeler code 00766, making all products under that labeler code Medi-Cal non-benefits. However, Nicoderm CQ products in distribution continue to carry the 00766 labeler code because the Universal Product Code (UPC) has not changed.

### Billing Update

Because products with the old NDC/UPC will remain on the market for a period of time, DHCS has decided to allow pharmacy providers to bill the corresponding 00135 labeler code for this product only, even though the package contains the older 00766 number, to avoid unnecessary denied claims and prior authorization submissions.

Providers may refer to the table below for the old NDC labeler code, its corresponding UPC and the new NDC for appropriate claims.

New NDC	Product Description	UPC	Count	Unit	Old 00766 NDC
00135-0195-02	NICODERM CQ 14 MG/24HR PATCH	307661430208	14.000	ea	00766143020
00135-0194-03	NICODERM CQ 21 MG/24HR PATCH	307661470204	21.000	ea	00766147020
00135-0145-01	NICODERM CQ 21 MG/24HR PATCH	307661450107	7.000	ea	00766145010
00135-0145-02	NICODERM CQ 21 MG/24HR PATCH	307661450206	14.000	ea	00766145020
00135-0194-01	NICODERM CQ 21 MG/24HR PATCH	307661420506	7.000	ea	00766142050
00135-0194-02	NICODERM CQ 21 MG/24HR PATCH	307661420209	14.000	ea	00766142020
00135-0196-02	NICODERM CQ 7 MG/24HR PATCH	307661440207	14.000	ea	00766144020

**Note:** NDC labeler code 00766 will be removed from the Code I restrictions.

### Reminder

This action is for Nicoderm CQ only. For all other drug products, providers must continue to bill the NDC on the package from which they are dispensing the product.

DHCS will continue to work with GSK for a permanent solution to this issue.

*This information is reflected on manual replacement page [drugs cdl p2 9 \(Part 2\)](#).*



**DRUG USE REVIEW**  
*Educational Information*


**Persistence of Beta-Blocker Treatment After Myocardial Infarction**

Myocardial infarction is classified as the death of a segment of the heart due to lack of blood supply. National statistics indicate there will be an estimated 700,000 Americans that suffer a myocardial infarction or other type of cardiac attack this year.<sup>1</sup> According to data collected by the National Center for Health Statistics, over the five-year period from 1999 through 2004, an estimated 7.9 million patients had an acute myocardial infarction (AMI).<sup>2</sup> The American Heart Association and American College of Cardiology both have guidelines for treatment after an AMI that recommend beta-blockers during the hospital stay and upon discharge for those patients who do not have contraindications to beta-blocker use. Beta-blockers decrease myocardial oxygen demand along with slowing heart rate and lowering blood pressure.

A retrospective study of Medi-Cal Fee-for-Service (FFS) recipients was conducted to measure the extent of compliance with treatment with beta-blocker medications after discharge from hospital after a heart attack. The study of Medi-Cal FFS recipients followed the study design prepared by the National Committee for Quality Assurance (NCQA) for HEDIS 2008.<sup>3</sup> The study, “Persistence of Beta-Blocker Treatment After a Heart Attack,” outlines the specific diagnosis codes used to identify acute myocardial infarction (AMI) along with the diagnosis codes to use for excluding patients where beta-blocker therapy would be contraindicated. Though the HEDIS study covered a 12-month period, Medi-Cal used a 9-month period to find those patients who had a heart attack, with an additional 6 months to track prescriptions for beta-blockers after their heart attack.

- 576 Medi-Cal FFS recipients met the criteria outlined in the HEDIS 2008 study for inclusion in this study.
  - Though 80% filled a prescription for beta-blocker medications within 180 days of their discharge from a hospital after suffering an AMI, only 32% met the HEDIS criteria for continuing treatment for 6 months following their heart attack
  - Over 53% of patients filled a prescription for beta-blocker medications within 30 days of discharge from hospital

**Patient Compliance with Beta-Blocker Prescriptions After Heart Attack**



*Please see Beta-Blocker Treatment, page 7*

**Beta-Blocker Treatment** *(continued)*

The Medi-Cal data shows that about one-half of patients are filling an initial prescription for beta-blocker after an AMI, but the long term, continuing treatment for their condition is not occurring. Because compliance is often an issue, physicians should be talking to their patients about the importance of taking medications as prescribed at every appointment. Pharmacists can also help monitor that patients are getting their beta-blockers refilled at appropriate time intervals and by asking patients how they are coping with any side effects that may be occurring due to the medication. This can occur when other prescriptions are picked up and possibly through mailed notices or phone reminders that their prescriptions needs to be refilled.

Medi-Cal recommends prescribers and other health professionals follow the most current recommendations by the American Heart Association and American College of Cardiology for treatment after a myocardial infarction. The most current recommendations can be found at: [www.americanheart.org/presenter.jhtml?identifier=3003999](http://www.americanheart.org/presenter.jhtml?identifier=3003999).

**References**

1. AHA/ASA Heart Disease and Stroke Statistics 2007 Update.
2. Rosamond, et al. Heart Disease and Stroke Statistics – 2007 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2007; 115; 69-171.
3. National Committee for Quality Assurance (NCQA). Persistence of Beta-Blocker Treatment After a Heart Attack. HEDIS 2008, Volume 2 Technical Specifications.

*Please refer to pages 36-41 and 36-42 in the Medi-Cal Drug Use Review manual.*

**Pharmacy Bulletin 662**

Remove and replace:   drugs cdl p1a 17/18  
                                  drugs cdl p1b 5/6, 13/14  
                                  drugs cdl p1c 3/4  
                                  drugs cdl p1d 21/22  
                                  drugs cdl p2 9/10  
                                  drugs cdl p5 5/6, 11 thru 15

Remove:                    mc sup lst1 13 thru 37  
Insert:                     mc sup lst1 13 thru 34

**DRUG USE REVIEW (DUR) MANUAL**

---

Insert in the  
*Education* section:       36-41/36-42